Prosecution Insights
Last updated: November 16, 2026
Application No. 19/122,105

INSTRUMENTS AND CORRESPONDING PROCEDURAL METHODS FOR PERFORMING PHOTOBIOMODULATION THERAPY

Non-Final OA §102§103§112
Filed
Apr 17, 2025
Priority
Oct 20, 2022 — AU 2022903093 +1 more
Examiner
LEE, ERICA SHENGKAI
Art Unit
3792
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Dentroid Pty Ltd.
OA Round
1 (Non-Final)
66%
Grant Probability
Favorable
1-2
OA Rounds
95%
With Interview

Examiner Intelligence

Grants 66% — above average
66%
Career Allowance Rate
407 granted / 621 resolved
-4.5% vs TC avg
Strong +30% interview lift
Without
With
+29.6%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
40 currently pending
Career history
675
Total Applications
across all art units

Office Action

§102 §103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Response to Amendment The preliminary amendment filed August 11, 2026 has been entered. Claims 1-68 are canceled. Claims 69-90 are new and currently pending for examination. Claim Objections Claim 77 is objected to because of the following informalities: lines 2 and 3 recite, “the light source(s)” suggesting encompassing multiple light sources. However independent claim 69 only introduces, “a light source”. Claim 77 should be amended to state, “the light source”. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 81 and 88 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 81 recites the limitation "the handle" in line 3. There is insufficient antecedent basis for this limitation in the claim. No handle has been introduced in the claims. Claim 88 recites the limitation “device controller” in lines 11-12. There is insufficient antecedent basis for this limitation in the claim. No remote controller has been introduced in the claims. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claim(s) 69, 72-77, 89 is/are rejected under 35 U.S.C. 102(a)(1) and/or (a)(2) as being anticipated by Diamantopoulos et al. (US 4,930,504). Regarding claim 69, Diamantopoulos et al. discloses an instrument for performing pre-emptive photobiomodulation (PBM) analgesia preceding or accompanying a medical or dental procedure, comprising: a body (fig. 4) comprising a light emitting portion (fig. 6); and a light source 80 (fig. 6) configured to emit light through the light emitting portion to target a site on the skin or mucosa of an animal, including a human, that is to undergo the pre-emptive photobiomodulation (PBM) analgesia, the light source configured to simultaneously emit light at multiple distinct peak wavelengths (“two or more wavelengths of radiation from the array 60 simultaneously pass through some point in the tissue 100 being stimulated” col. 40-43) falling within a spectral range of 615nm to 1100nm with at least one of the distinct peak wavelengths falling within a near-infrared spectral range of between about 900nm to 1100nm and at least one other one of the distinct peak wavelengths falling within a spectral range of between about 615nm to 900nm (col. 6, line 45 to col. 7, line 36). Regarding claim 72, Diamantopoulos et al. discloses wherein the light source is configurable by an operator to dynamically adjust at least one of an emitted power, peak wavelength power distribution, and pulse modulation for achieving a desired level of PBM analgesia (col. 9, 38-61). Regarding claim 73, Diamantopoulos et al. discloses wherein the light source comprises a multi-wavelength emitter (col. 6, line 45 to col. 7, line 36). Regarding claim 74, Diamantopoulos et al. discloses wherein the light source comprises a plurality of LEDs (fig. 6-8) configured to emit light at the respective peak wavelengths (col. 6, line 45 to col. 7, line 36). Regarding claim 75, Diamantopoulos et al. discloses further comprising a controller 70 (fig. 4) configured to selectively control at least one of a pulse frequency and pulse energy of the light source sufficient to produce pre-emptive PBM analgesia (col. 9, lines 48-61). Regarding claim 76, Diamantopoulos et al. discloses wherein the controller is configured to set a duty cycle for the emitted light (col. 6, line 40-41). Regarding claim 77, Diamantopoulos et al. discloses wherein the controller operates the light source in pulsed mode and preferably wherein pulsing is achieved by electrical current pulse, or chopping a continuous wave beam emitted by the light source (col. 9, lines 48-61). Regarding claim 89, Diamantopoulos et al. discloses a method of administering pre-emptive photobiomodulation (PBM) analgesia comprising: providing an instrument for performing pre-emptive photobiomodulation (PBM) analgesia preceding or accompanying a medical or dental procedure, comprising: a body (fig. 5) comprising a light emitting portion (fig. 6); and a light source 80 (fig. 6) configured to emit light through the light emitting portion to target a site on the skin or mucosa of an animal, including a human, that is to undergo the pre-emptive photobiomodulation (PBM) analgesia, the light source configured to simultaneously emit light at multiple distinct peak wavelengths (“two or more wavelengths of radiation from the array 60 simultaneously pass through some point in the tissue 100 being stimulated” col. 40-43) falling within a spectral range of 615nm to 1100nm with at least one of the distinct peak wavelengths falling within a near-infrared spectral range of between about 900nm to 1100nm and at least one other one of the distinct peak wavelengths falling within a spectral range of between about 615nm to 900nm (col. 6, line 45 to col. 7, line 36); and controlling the light source to emit light to the target site for administering pre-emptive photobiomodulation (PBM) analgesia (col. 9, 38-61). Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim(s) 70 is/are rejected under 35 U.S.C. 103 as being unpatentable over Diamantopoulos et al. (US 4,930,504) in view of Parker et al. (US 2017/0361124). Regarding claim 70, Diamantopoulos et al. does not expressly disclose wherein the light source is further configured such that a relative power distribution for the emitted light is weighted toward one or more longer ones of the wavelengths within the spectral range. Parker et al. teaches an analogous photobiomodulation device where an example spectral power distribution (fig. 2a) is provided describing wavelength ranges where the relative power distribution for emitted light is weighted toward longer wavelengths (800 nm) as compared to shorter wavelengths (600 nm). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify Diamantopoulos et al. to select a relative power distribution for the emitted light is weighted toward one or more longer ones of the wavelengths within the spectral range as taught by Parker et al. as selecting these specific weights is no more than a mere design choice, selected from a finite number of choices, the results of such a modification being reasonably predictable. Claim(s) 71, 80-83, 90 is/are rejected under 35 U.S.C. 103 as being unpatentable over Diamantopoulos et al. (US 4,930,504). Regarding claims 71 and 90, Diamantopoulos et al. discloses a minimum treatment energy density of 7.2 Joules/cm2 is achievable with the instrument (col. 9, lines 45-47). It appears that one of ordinary skill in the art at the effective filing date of the claimed invention would have had a reasonable expectation of success in modifying the instrument to have a radiant exposure of light delivered to the target tissue falling between about 8 to 12 Joules/ cm2, as it involves only adjusting the parameters of stimulation disclosed to require adjustment. Therefore it would have been obvious to one having ordinary skill in the art before the effective filing date of the claimed invention to modify the instrument of Diamantopoulos et al. to have a radiant exposure of light delivered to the target tissue falling between about 8 to 12 Joules/ cm2 as a matter of routine optimization since it has been held that “where the general working conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation.” In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955). Regarding claim 80, Diamantopoulos et al. discloses the light emitting portion is disposed on a head (fig. 6) which is in turn connected to the body (fig. 4) via an elongated neck 46 (col. 4, lines 30-31). One of ordinary skill in the art before the effective filing date of the claimed invention would have thought the head and at least a portion of the neck of the instrument capable of being inserted into the patient’s oral cavity for administering pre-emptive PBM dental analgesia in order to more effectively treat dental pain and swelling (col. 11, line 54). Regarding claim 81, Diamantopoulos et al. discloses wherein at least a portion of the neck 62 (“output line” col. 4, lines 30-31) and/or light emitting head is curved or otherwise has a longitudinal axis that is offset (fig. 4) with respect to a longitudinal axis of the handle (35 U.S.C. 112 rejection) thereby allowing the light emitting head to be capable of accessing posterior areas of the oral cavity. Regarding claim 82, Diamantopoulos et al. discloses wherein the light source is further configured to emit light at wavelengths in the visible and/or red spectrums (col. 3, lines 7-10) for performing one or more additional dental functions selected from the group comprising: white light examination; near infrared (NIR) transillumination; fluorescence check; light curing; photocoagulation and photodynamic therapy (col. 11, lines 46-57). Regarding claim 83, Diamantopoulos et al. discloses wherein the light source is integrated into at least one of the head (fig. 5) and neck of the instrument and wherein the head/neck is configured to be detachably coupled to the body (fig. 4) via an electrical coupling 62, thereby allowing the light source to be powered and controlled (col. 4, lines 20-32). Claim(s) 78-79, 84, 88 is/are rejected under 35 U.S.C. 103 as being unpatentable over Diamantopoulos et al. (US 4,930,504) and further in view of Hetz (US 2022/0176148). Regarding claim 78, Diamantopoulos et al. does not expressly disclose wherein for dental applications, the light emitting portion has an effective area of between about 0.2 cm2 to 0.8 cm2. Hetz teaches an analogous instrument (“probe”) for performing photobiomodulation where simultaneous wavelengths of light are delivered to tissues being treated ([0325]), the probe emitting a beam that can be tailored to the patient, for example, the beam could have a width of 0.1 cm to 5 cm ([0390]), suggesting that as a circular beam, the effective area of the light emitting portion would be between 0.2 cm2 to 0.8 cm2. It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify Diamantopoulos et al. to configure the effective area of the light emitting portion to be between 0.2 cm2 to 0.8 cm2 As Hetz teaches these parameters are known in the art as appropriate for treating via PBM. Regarding claim 79, Diamantopoulos et al. does not expressly disclose a temperature sensor and display means configured to output a temperature reading. Hetz teaches an analogous instrument (“probe”) for performing photobiomodulation where a temperature sensor is provided with the probe ([0338]) to capture tissue or skin temperature information ([0245-0246]) and a display means to output a temperature reading ([0366]). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify Diamantopoulos et al. to include a temperature sensor and display as taught by Hetz in order to better monitor the treatment area and communicate temperature readings. Regarding claim 84, Diamantopoulos et al. does not expressly disclose wherein the light source is integrated into the body and wherein optical fibre(s) within the neck and head act as light guides for transmitting the emitted light through and out of the head for targeted delivery to the site. Hetz teaches an analogous instrument (“probe”) for performing photobiomodulation where a light source of the instrument is integrated in a body 3216 and optical fibers 3209 then act as light guides to transmit the light through the neck and out of a head of the instrument ([0500]; fig. 65-66). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to configure the instrument of Diamantopoulos et al. such that the light source is integrated into the body and wherein optical fibre(s) within the neck and head act as light guides for transmitting the emitted light through and out of the head for targeted delivery to the site as Hetz teaches this arrangement is known in the art for performing the same function of delivering PBM to tissue/skin, and the results of such a known configuration would have been reasonably predictable in the art. Regarding claim 88, Diamantopoulos et al. discloses a pre-emptive photobiomodulation (PBM) analgesia system, comprising: an instrument (fig. 4) for performing pre-emptive photobiomodulation (PBM) analgesia preceding or accompanying a medical or dental procedure, comprising: a body (fig. 5) comprising a light emitting portion (fig. 6); and a light source 80 (fig. 6) configured to emit light through the light emitting portion to target a site on the skin or mucosa of an animal, including a human, that is to undergo the pre-emptive photobiomodulation (PBM) analgesia, the light source configured to simultaneously emit light at multiple distinct peak wavelengths (“two or more wavelengths of radiation from the array 60 simultaneously pass through some point in the tissue 100 being stimulated” col. 40-43) falling within a spectral range of 615nm to 1100nm with at least one of the distinct peak wavelengths falling within a near-infrared spectral range of between about 900nm to 1100nm and at least one other one of the distinct peak wavelengths falling within a spectral range of between about 615nm to 900nm (col. 6, line 45 to col. 7, line 36). Diamantopoulos et al. does not expressly disclose a remote controller configured to wirelessly communicate with the instrument or device controller (35 U.S.C. 112 rejection) for remote control thereof. Hetz teaches an analogous instrument (“probe”) for performing photobiomodulation where simultaneous wavelengths of light are delivered to tissues being treated ([0325]), the probe 3201 being communicatively connected wirelessly to a remote device 3217 for remote control of the instrument ([0500-0501]; fig. 66). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify Diamantopoulos et al. to include a remote controller configured to wirelessly communicate with the instrument for remote control thereof as taught by Hetz in order to provide a robust controller that can connect to a variety of other electronics architecture ([0487]) and can provide media information such as video or photographs to a user ([0554]). Claim(s) 85-87 is/are rejected under 35 U.S.C. 103 as being unpatentable over Diamantopoulos et al. (US 4,930,504) and further in view of Shalev et al. (US 2021/0030503). Regarding claim 85, Diamantopoulos et al. does not expressly disclose the outer surface of the instrument comprises a contamination barrier. Shalev et al. teaches barrier devices for medical devices are known in the art to reduce the chances of cross-contamination and to protect the medical device from damage ([0007]). Given Diamantopoulos et al. discloses the instrument may be used for dental treatment (col. 11, lines 50-57), it would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the instrument and include a contamination barrier as taught by Shalev et al. in order to better protect the instrument and to reduce cross-contamination between users. Regarding claim 86, Diamantopoulos et al. in view of Shalev et al. disclose wherein the outer surface is sealable ([0010]). Regarding claim 87, Diamantopoulos et al. in view of Shalev et al. disclose a protective sleeve configured to at least partially cover the outer surface to thereby operate as the contamination barrier ([0007]). Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to ERICA S LEE whose telephone number is (571)270-1480. The examiner can normally be reached M-F 8-7pm, flex. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, David Hamaoui can be reached at (571) 270-5625. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ERICA S LEE/Primary Examiner, Art Unit 3796
Read full office action

Prosecution Timeline

Apr 17, 2025
Application Filed
Aug 11, 2026
Response after Non-Final Action
Oct 28, 2026
Non-Final Rejection mailed — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12779242
METHOD AND DEVICE FOR GENERATING ANTICANCER MATERIAL IN LIVING BODY
3y 11m to grant Granted Nov 03, 2026
Patent 12779221
COCHLEAR IMPLANTS INCLUDING VIBRATION DRIVEN ELECTRODE ARRAYS AND ASSOCIATED METHODS
3y 2m to grant Granted Nov 03, 2026
Patent 12773553
COCHLEAR IMPLANT SYSTEM WITH ELECTRODE IMPEDANCE DIAGNOSTICS
2y 10m to grant Granted Oct 27, 2026
Patent 12773554
METHODS AND PHARMACEUTICAL FORMULATIONS FOR MODULATING THE PROPERTIES OF THE BLOOD LABYRINTH BARRIER
2y 10m to grant Granted Oct 27, 2026
Patent 12765827
ELECTROPHYSIOLOGICAL CATHETER SYSTEMS
4y 8m to grant Granted Oct 20, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
66%
Grant Probability
95%
With Interview (+29.6%)
Low
PTA Risk
Based on 621 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month